Total Tau (T Tau) Biomarker is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
| Property | Value |
|---|---|
| Category | Protein Biomarker |
| Target | Total tau protein |
| Sample Type | CSF, Plasma |
| Diseases | Alzheimer's Disease, CTE, TBI, ALS |
| Clinical Utility | Axonal damage, neurodegeneration |
Total tau (t-tau) is a core cerebrospinal fluid (CSF) biomarker that measures the concentration of all tau protein isoforms in the brain[1]. Unlike phosphorylated tau (p-tau), which reflects tau pathology specifically, total tau provides a general marker of neuronal and axonal damage[2].
Tau is a microtubule-associated protein encoded by the MAPT gene (Microtubule-Associated Protein Tau) located on chromosome 17q21[3]. In the human brain, tau exists as six isoforms ranging from 352 to 441 amino acids, generated by alternative splicing of exons 2, 3, and 10. The protein plays essential roles in:
Under pathological conditions, tau becomes hyperphosphylated at multiple sites (over 45 potential phosphorylation sites have been identified), leading to microtubule dysfunction and neurofibrillary tangle formation[4]. The balance between kinase activity (GSK-3β, CDK5) and phosphatase activity (PP2A) regulates tau phosphorylation state.
In AD, CSF t-tau is elevated due to neuronal death and axonal degeneration. It correlates with:
However, t-tau is less specific than p-tau for AD diagnosis, as elevations occur in other neurodegenerative conditions. The combination of t-tau with Aβ42/Aβ40 ratio and p-tau provides optimal diagnostic accuracy[10].
t-Tau is a promising biomarker for:
Studies in professional hockey players have shown elevated t-tau following concussion, with levels remaining elevated for several days post-injury.
| Condition | t-tau Level | p-tau Level | t-tau/p-tau Ratio |
|---|---|---|---|
| Alzheimer's Disease | Elevated | Elevated | Normal |
| FTD | Moderately Elevated | Normal | Elevated |
| DLB | Normal-Elevated | Normal-Elevated | Normal |
| CJD | Very High | Normal | Very High |
This differential diagnostic table highlights the utility of the t-tau/p-tau ratio in distinguishing CJD from other dementias[12].
The presence of t-tau in cerebrospinal fluid reflects the continuous turnover of neuronal tau protein under normal conditions. Pathological elevations occur through several mechanisms:
The balance between production and clearance determines measured CSF concentrations. In AD, increased release (from neurodegeneration) combined with potentially impaired clearance leads to elevated levels.
The six tau isoforms (2N4R, 2N3R, 2N2R, 1N4R, 1N3R, 1N2R, 0N4R, 0N3R, 0N2R) are all present in CSF. The relative proportions can provide disease-specific information:
The discovery of t-tau in CSF represented a major milestone in neurodegenerative disease biomarker research. Early studies in the 1990s demonstrated that t-tau was elevated in AD patients compared to controls, establishing the foundation for modern CSF biomarker research. Key historical milestones include:
t-tau provides important prognostic information:
Studies show that t-tau in preclinical AD (cognitively normal individuals with biomarker evidence of AD pathology) can predict subsequent cognitive decline, with higher baseline levels associated with greater risk of progression to MCI or AD[15].
Serial t-tau measurements can track disease progression:
The rate of t-tau change correlates with clinical progression rates, making it useful for patient stratification in clinical trials and clinical management.
Pediatric Applications
Athletes and TBI
| Feature | t-tau | p-tau 181 |
|---|---|---|
| Specificity for AD | Low-Moderate | High |
| Reflects | Neuronal damage | Tau pathology |
| Diagnostic Accuracy (AD) | 75-85% AUC | 90-95% AUC |
| Elevated in | Multiple conditions | Primarily AD |
| Clinical Use | Neurodegeneration marker | AD-specific marker |
| Feature | t-tau | NfL |
|---|---|---|
| Protein Family | Microtubule-associated | Neurofilament |
| Specificity | Moderate | Low |
| Primary Use | AD, CTE | All neurodegeneration |
| Change Kinetics | Gradual | Acute + chronic |
Both biomarkers provide complementary information about neurodegeneration. NfL shows more acute changes while t-tau reflects chronic neuronal loss.
When selecting biomarkers for clinical or research use:
Proper sample handling is critical for accurate t-tau measurement:
Deviations from standard protocols can affect results significantly. Studies show that improper handling can cause 20-30% variability in measured values.
Efforts are underway to standardize t-tau measurements across laboratories:
Until standardization is complete, use of centralized laboratories or consistent platforms is recommended for longitudinal monitoring.
The development of ultra-sensitive blood tests for t-tau is an active research area:
Blood t-tau shows promise for screening and monitoring but is not yet validated for clinical use.
Research is exploring optimal biomarker combinations:
These combinations may improve diagnostic accuracy and provide more comprehensive disease characterization.
Appropriate clinical scenarios include:
| t-tau Level (pg/mL) | Interpretation |
|---|---|
| <200 | Normal |
| 200-300 | Borderline (age consideration) |
| 300-500 | Mild elevation (consider FTD, vascular) |
| 500-1000 | Moderate elevation (likely AD or mixed) |
| >1000 | High (consider CJD or significant injury) |
Always interpret in clinical context and with accompanying biomarkers (Aβ42/40, p-tau).
Blennow K, et al. (2015). Clinical utility of cerebrospinal fluid biomarkers in the diagnosis of early Alzheimer's disease. Alzheimer's & Dementia. 2015. ↩︎
Zetterberg H. (2017). Review: Tau in biofluids - relation to CSF tau. Journal of Alzheimer's Disease. 2017. ↩︎
Goedert M, et al. (1989). Tau proteins: function and pathology in neurodegenerative diseases. Trends in Neurosciences. 1989. ↩︎
Mandelkow E, Mandelkow E. (2012). Biochemistry and cell biology of tau protein in neurofibrillary degeneration. Cold Spring Harbor Perspectives in Medicine. 2012. ↩︎
Olsson B, et al. (2016). CSF and blood biomarkers for the diagnosis of Alzheimer's disease. Lancet Neurology. 2016. ↩︎
Shahim P, et al. (2016). Blood biomarkers for brain injury in concussed professional hockey players. JAMA Neurology. 2016. ↩︎
Skillback T, et al. (2015). Cerebrospinal fluid tau and neurofilament light chain protein levels in patients with CJD. JAMA Neurology. 2015. ↩︎
Buchhave P, et al. (2012). Cerebrospinal fluid total tau as a marker of disease intensity. Neurology. 2012. ↩︎
Hampel H, et al. (2010). Core biochemical marker for axonal injury. Neurology. 2010. ↩︎
Hansson O, et al. (2018). CSF biomarkers for Alzheimer's disease. Lancet Neurology. 2018. ↩︎
Zetterberg H. (2016). Tau biochemistry and its implications for traumatic brain injury. Annals of Neurology. 2016. ↩︎
Rascovsky K, et al. (2011). Diagnostic accuracy of tau protein in CSF. Neurology. 2011. ↩︎
Bancher C, et al. (1999). Tau proteins in CSF. J Neural Transm Suppl. 1999. ↩︎
Blennow K, et al. (2019). Wet biomarker analysis. Nat Rev Neurol. 2019. ↩︎
Mattsson N, et al. (2019). Plasma tau in preclinical Alzheimer's disease. JAMA Neurology. 2019. ↩︎